Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.40 |
| ▸ | GABRE | P78334 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24159031 | 0.84 | P2RX7 (0.47) | KDM4EP2RX7LMNAFFAR1L3MBTL1 | |
| SCHEMBL2827976 | 0.81 | LMNA (0.46) | KDM4EP2RX7LMNAFFAR1L3MBTL1 | |
| SCHEMBL21576140 | 0.81 | P2RX7 (0.48) | KDM4EP2RX7LMNAFFAR1L3MBTL1 | |
| SCHEMBL3940461 | 0.81 | P2RX7 (0.48) | KDM4EP2RX7FFAR1SMN1; SMN2DAO | |
| SCHEMBL8145392 | 0.81 | NR1H4 (0.43) | KDM4EP2RX7NPSR1NR1H4FFAR1 | |
| SCHEMBL21570111 | 0.80 | LMNA (0.49) | KDM4EP2RX7LMNAFFAR1L3MBTL1 | |
| SCHEMBL22437429 | 0.79 | NR1H4 (0.48) | KDM4ENPSR1NR1H4LMNAL3MBTL1 | |
| SCHEMBL25303381 | 0.79 | KDM4E (0.51) | KDM4ENPSR1LMNAL3MBTL1GABRP | |
| SCHEMBL19634920 | 0.77 | P2RX7 (0.40) | P2RX7FFAR1SMN1; SMN2DAOHSD17B10 | |
| SCHEMBL14319133 | 0.76 | NR1H4 (0.51) | KDM4ENPSR1NR1H4L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-117304130-A | MCL-1 inhibitors | 吉利德科学公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| CN-112118845-B | MCL-1 inhibitors | 吉利德科学公司 | 2023-06-13 | — | — | CN | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220340535-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-4029868-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3793565-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-10988451-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3793565-A1 | MCL-1 INHIBITORS | Gilead Sciences, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| CN-112118845-A | MCL-1 inhibitors | 吉利德科学公司 | 2020-12-22 | — | — | CN | disclosed |
| US-20200331870-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10703733-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352271-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | KDM4E 2079/4885P2RX7 4351/4885NPSR1 4702/4885 |
| US-20200331870-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | KDM4E 2079/4885P2RX7 4351/4885NPSR1 4702/4885 |
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | KDM4E 2079/4885P2RX7 4351/4885NPSR1 4702/4885 |
| US-10703733-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | KDM4E 2079/4885P2RX7 4351/4885NPSR1 4702/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | KDM4E 2079/4885P2RX7 4351/4885NPSR1 4702/4885 |
| US-10988451-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | KDM4E 2079/4885P2RX7 4351/4885NPSR1 4702/4885 |
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | KDM4E 3977/4885P2RX7 2031/4885NPSR1 876/4885 |
| US-20220340535-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | KDM4E 2079/4885P2RX7 4351/4885NPSR1 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.